GGrantIndex
Sort

21,281 grants matching influenza

GH16-006: Conducting Public Health Research in Kenya

$1,438,500
Christopher D Bayer · Hjf Medical Research International, Inc. · U01 · FY2019 · GH

NOVEL CELLULAR AND VIRAL TARGETS FOR ANTI-INFLUENZA VIRUS DRUGS

$1,435,679
Peter Palese · Icahn School Of Medicine At Mount Sinai · U01 · FY2009 · AI

Laboratory And Pre-clinical Studies Of Parainfluenza Viruses

$1,435,433
Peter Leon Collins · National Institute Of Allergy And Infectious Diseases · ZIA · FY2016 · AI

VACCINE ADJUVANT DISCOVERY PROGRAM (VADP)

$1,435,380
Ofer Levy · Boston Children'S Hospital · N01 · FY2024 · AI

A Phase 1/2a, randomized study of a Tfh-targeting genetic vaccine adjuvant designed to induce broad, durable immune responses

$1,435,214
Kara W Chew · University Of California Los Angeles · U01 · FY2024 · AI

GH13-003: Hospital - Based Surveillance of Acute Febrile Illness in Western Ghat Region of

$1,434,000
Arunkumar Govindakarnavar · Manipal Academy Of Higher Education · U01 · FY2017 · GH

Innate Immunity and Viral Infection in Asthma

$1,433,547
Monica Kraft · University Of Arizona · U19 · FY2021 · AI

Collaborative Influenza Vaccine Innovation Centers STATISTICAL, DATA MANAGEMENT AND COORDINATION CENTER (SDMCC)

$1,432,309
Stephan Bour · Digital Infuzion, Inc. · N01 · FY2020 · AI

Innate Immunity and Viral Infection in Asthma

$1,431,641
Monica Kraft · University Of Arizona · U19 · FY2023 · AI

Innate Immunity and Viral Infection in Asthma

$1,431,641
Monica Kraft · University Of Arizona · U19 · FY2022 · AI

Innate Immunity and Viral Infection in Asthma

$1,431,641
Monica Kraft · University Of Arizona · U19 · FY2024 · AI

Innate Immunity and Viral Infection in Asthma

$1,431,641
Monica Kraft · University Of Arizona · U19 · FY2025 · AI

Human Mab Cocktails to Prevent & Treat H5N1 Avian Influenza

$1,430,391
Wayne A. Marasco · Dana-Farber Cancer Inst · U01 · FY2011 · AI

Development of drugs that target the M2 proton channel from the influenza A Virus

$1,430,000
William F Degrado · University Of Pennsylvania · U01 · FY2008 · AI

Collaborative Influenza Vaccine Innovation Centers STATISTICAL, DATA MANAGEMENT AND COORDINATION CENTER (SDMCC)

$1,429,508
Stephan Bour · Digital Infuzion, Inc. · N01 · FY2019 · AI

Vanderbilt Vaccine and Treatment Evaluation Unit

$1,427,717
Clarence Buddy Creech · Vanderbilt University Medical Center · UM1 · FY2024 · AI

Innate inflammatory responses during pulmonary infections

$1,427,583
Katrin Mayer-Barber · National Institute Of Allergy And Infectious Diseases · ZIA · FY2023 · AI

NOVEL CELLULAR AND VIRAL TARGETS FOR ANTI-INFLUENZA VIRUS DRUGS

$1,427,583
Peter Palese · Icahn School Of Medicine At Mount Sinai · U01 · FY2011 · AI

High-throughput identification of antibody features for sequence-based epitope prediction

$1,427,400
Nicholas C. Wu · University Of Illinois At Urbana-Champaign · DP2 · FY2021 · AT

Preclinical development of semisynthetic saponin immunological adjuvant Titerquil-1055 in the context of an influenza vaccine

$1,427,022
Tyler Martin · Adjuvance Technologies, Inc. · N43 · FY2019 · AI

SBIR Phase II: Stress Pathway Inhibition To Prevent COVID-19 Infection (COVID-19)

$1,427,000
Donald J Davidson · Creative Biotherapeutics Llc · · FY2022 · TIP

CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS)

$1,425,978
John Jay Treanor · University Of Rochester · N01 · FY2018 · AI

Discovery of novel synthetic IL-1 adjuvants

$1,425,708
Jay Evans · University Of Montana · N01 · FY2019 · AI

Influenza Vaccine Development

$1,425,675
Gary J Nabel · National Institute Of Allergy And Infectious Diseases · ZIA · FY2009 · AI

Paramyxoviruses as Vaccine Vectors Against Highly Pathogenic Viruses

$1,425,149
Peter Leon Collins · National Institute Of Allergy And Infectious Diseases · ZIA · FY2009 · AI